middle.news
PYC positions four genetic disease programs for 2027 clinical milestones
8:38am on Thursday 29th of October, 2026 AEDT
•
Biotechnology
Read Story
PYC positions four genetic disease programs for 2027 clinical milestones
8:38am on Thursday 29th of October, 2026 AEDT
Key Points
PYC-003 advanced to 2.4 mg/kg dosing and a 24-month open-label extension in PKD
PYC-002 entered GLP toxicology studies ahead of expected human trials in 2027
PYC reported clinical or pre-clinical data updates for ADOA and RP11 programs
$655 million held across cash, term deposits and liquid financial assets
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PYC Therapeutics (ASX:PYC)
OPEN ARTICLE